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Abstract
Blockchain is a shared distributed digital ledger technology that can better facilitate data management, provenance
and security, and has the potential to transform healthcare. Importantly, blockchain represents a data architecture,
whose application goes far beyond Bitcoin – the cryptocurrency that relies on blockchain and has popularized the
technology. In the health sector, blockchain is being aggressively explored by various stakeholders to optimize
business processes, lower costs, improve patient outcomes, enhance compliance, and enable better use of
healthcare-related data. However, critical in assessing whether blockchain can fulfill the hype of a technology
characterized as ‘revolutionary’ and ‘disruptive’, is the need to ensure that blockchain design elements consider
actual healthcare needs from the diverse perspectives of consumers, patients, providers, and regulators. In
addition, answering the real needs of healthcare stakeholders, blockchain approaches must also be responsive to
the unique challenges faced in healthcare compared to other sectors of the economy. In this sense, ensuring that
a health blockchain is ‘fit-for-purpose’ is pivotal. This concept forms the basis for this article, where we share
views from a multidisciplinary group of practitioners at the forefront of blockchain conceptualization, development,
and deployment.
Keywords: Blockchain, Distributed ledger technology, Healthcare technology, Health informatics, Supply chain, Clinical
trials, Medical licensure, Genomics, Electronic health records
Background
Tim Mackey (Fig. 1)
Whether you are a clinician, researcher, entrepreneur,
administrator, or executive, you are probably familiar
with the term ‘blockchain’. At its core, blockchain is a
new type of digital architecture, consisting of a shared,
immutable ledger that can better ensure the resilience,
provenance, traceability, and management of health data.
It has been hailed as a revolutionary technology, but
whether it meets this potential remains to be tested.
To understand blockchain’s potential for healthcare,
we first need to understand some basic technical
elements. Unlike traditional centralized databases, data
on a blockchain can be distributed across multiple data-
bases/computers (also known as ‘nodes’) so that every-
one has the same copy (ledger) of a transaction [1].
‘Blocks’ of data are linked together by a hash (a digital
signature of random letters and numbers) to form a
‘chain’ of data that contains the complete history of the
transaction and renders it tamper resistant [2, 3]. Block-
chain data is also secured through cryptography (ad-
vanced encryption) so that participants can trust that
‘blocks’ of data are authenticated and verifiable [2].
These technological features result in decentralized data
systems (not held by a central authority vulnerable to
breach or potentially acting as a single point of failure),
represent a single source of information among all par-
ticipants, and have inherently higher levels of trust (as
transactions are immutable, secure, and subject to con-
sensus of the participants). Blockchains can also be
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permissioned to limit participation and access to or
sharing of data [4]. Finally, there are public blockchains
(e.g., public network-based blockchains such as the
popular cryptocurrency Bitcoin) and private or ‘business’
blockchains (e.g., private networks not open to the pub-
lic but instead used by a select group of trusted partici-
pants) [5]. Some popular platforms for blockchain
deployment include Ethereum and Hyperledger, though
offerings are growing.
Beyond these core features, blockchains can also en-
able other technologies such as distributed applications
(those that run on multiple computers in a network) and
smart contracts (computer code that can execute terms
of a contract between parties) as well as the use of cryp-
tocurrencies (digital or virtual currencies) [2, 6–8].
Blockchains can also act as a digital backbone for other
technologies able to interface with blockchain systems
such as cloud computing, artificial intelligence, eHealth
and mHealth devices/applications, and the broader
Internet of Medical Things (IoMT) [6, 9, 10]. Thus, the
blockchain environment is expansive and modular, and
has the flexibility to be adopted for various use cases in
healthcare and beyond (see technology architecture
summary in Fig. 2).
Reflecting the increased attention given to blockchain in
healthcare and life sciences, the number of PubMed
indexed articles including the keyword ‘blockchain’ in the
title or abstract fields has increased dramatically, from
only 5 in 2016 to 64 in 2018 (Fig. 3). The published papers
evidence the wide variety of use cases that are being
researched for health blockchains, including management
and interoperability of healthcare data (e.g., patient health-
care, consumer health, and hospital data), improving in-
tegrity of published research, clinical trial management,
use and integration into IoMT applications (including
mHealth and remote patient monitoring), advancing gen-
omics and precision medicine, applications for biomedical
and medical education and research, pharmaceutical
supply chain management and security, implications of
blockchain for global health, and general articles of the
various opportunities for blockchain in medicine, engin-
eering and the life sciences [3–5, 7, 11–24]. However, it is
important to note that the published literature represents
only a snapshot of global blockchain activity, as many
health-related blockchain projects are published in white
papers, news articles, press releases, presented at confer-
ences, or are otherwise undisclosed as they are developed
for commercialization purposes. Several large technology
firms, such as IBM, Intel, and Microsoft, are heavily
invested in blockchain technology development, and the
World Economic Forum estimates that, by 2025, 10% of
the global gross domestic product will be stored on block-
chain technology [25].
Despite blockchain’s potential as an emerging technol-
ogy to be innovative and disruptive, it remains imma-
ture, particularly in healthcare. According to Gartner
[26], blockchain technology is in a ‘hype cycle’ character-
ized by stages of innovation triggers, inflated expecta-
tions, disillusionment, enlightenment, and ending in a
“plateau of productivity”, with healthcare and life sci-
ences currently squarely in the middle of phase one and
two of the curve. Reflecting the fact that it is still early
days for health blockchains, there are few real-world ex-
amples of blockchain systems that have gone into pro-
duction and that also have strong commercial or user
adoption in healthcare. In contrast, other sectors of the
economy have seen much faster adoption, including
Fig. 1 Tim K. Mackey is an Associate Professor at UC San Diego
School of Medicine, the Director of Healthcare Research and Policy
at UC San Diego Extension, and the Director of the Global Health
Policy Institute (www.ghpolicy.org). He has a multidisciplinary
background, with a research focus on global health policy, law,
governance, innovation and technology, and has worked or
consulted for organizations including the World Health Organization,
the US Department of State, and the US Department of Justice,
among others. He is also the co-Chair of the IEEE Standards
Association Supply Chain/Clinical Trials Technology Implementation
Industry Connections Program, which focuses on stakeholder
collaboration around blockchain technology for the pharmaceutical
supply chain and is also a Lab Principal Faculty with the BlockLab at the
San Diego Supercomputer Center
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Fig. 2 Depiction of blockchain data architecture components. This includes the core functions of blockchain data by generation of a first (genesis)
block that is timestamped and may include certain transaction data/metadata (transation data) or state-of-data information. These blocks of data are
chained together via a cryptographic hash of the data. The data layer represents where data can reside on the blockchain, primarily either storing data
on the blockchain itself (on-chain storage) or storing the data in a different source but including a pointer or using a distributed application as an
intermediary (off-chain storage). The core functions of the blockchain should also assess certain design considerations (in far right yellow box),
including whether the blockchain is public, private or consortium, the consensus mechanism to be used, the type of permissions structure, where data
should reside and how it should be managed, and the governance of the blockchain (who are the users, peers, validators, nodes, etc.). Finally, a
feature layer including blockchain-enabled technology options, such as the use of cryptocurrencies/tokens, digital wallets, smart contracts, and
distributed applications, can also be added if needed for a particular healthcare use case
Fig. 3 Summary statistics of publications with the term ‘blockchain’ in the Title or Abstract field in PubMed Central (as of December 1, 2018). a A
depiction of the increase in the number of blockchain publications from 2016 to 2018. b A breakdown of the health and life science categories
of blockchain publications, including healthcare data, clinical trials, medical education and research, supply chain, biomedical research, genomics,
Internet of Medical Things (IoMT), and general articles about blockchain applications in healthcare. Non-health articles included those discussing
blockchain in other industries such as energy, finance (cryptocurrencies), non-health supply chains, Internet of Things (non-health), news and
media, and ecology
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financial technology services and supply chain and
logistics.
Despite the core characteristics of decentralization, se-
curity, provenance, transparency, trust, and better man-
agement of data being clear benefits to address acute
healthcare needs, an approach that ensures that block-
chain technology is ‘fit-for-purpose’ for specific and di-
verse healthcare challenges is required. Importantly,
when assessing the viability of a blockchain for health,
what core blockchain characteristics and design princi-
ples need to be taken into account, and how can they
address the real-world legal, regulatory, privacy, busi-
ness, and provider and patient-centric considerations
unique to healthcare?
In an attempt to address these challenges, this Forum
article presents a ‘fit-for-purpose’ health blockchain design
framework that includes fundamental questions regarding
basic blockchain design principles, data sharing and man-
agement, and decisions about governance, as well as ex-
ploring the technologies that can be used to enhance
blockchain function and defining the ultimate goal for the
blockchain solution. If these questions can be appropri-
ately mapped, then there is a higher likelihood that the
blockchain approach will be ‘fit-for-purpose’ for whatever
healthcare challenge has been identified. The framework
questions are based on six principles, as follows:
1. Blockchain design types: Decision of whether
your blockchain design will be a public blockchain
(generally open to participation by anyone and not
permissioned), private blockchain (involving limited
participation and having permission structures), or
a hybrid (blockchain systems with both public and
private designs).
2. Data sharing and access: In healthcare, sharing
and access to health-related data is subject to
various privacy, legal, and regulatory requirements
(such as the Health Insurance Portability and
Accountability Act (HIPAA) and the General Data
Protection Regulation (GDPR)). Decisions need to
be made about what type of data will be shared with
and among participants, if any, whether data will be
stored on-chain, off-chain or on a side-chain, and
the type of permission structures that will be
utilized.
3. Decisions about blockchain governance:
Governance is a crucial component to the design
of a blockchain system. The nodes, users, peers,
and/or validators of the blockchain will need to be
defined, as well as whether it will be comprised of
only trusted partners, a consortium of participants,
or participation of public entities or regulators, and
include patients/consumers/the public. Finally, how
these actors will make decisions about how to
govern the blockchain (including choices regarding
consensus mechanisms, permissions, and data
governance) will also need defining.
4. Added technology to enhance blockchain
function: As previously discussed, the blockchain
architecture can also enable the use of other
technologies, including the development of an
application layer that interfaces with the blockchain,
the use of smart contracts to automate processes
when certain agreed upon conditions are met, and
the use of a cryptocurrency/tokens to incentivize
participation that ideally provides shared benefits to
all participants.
5. Ultimate healthcare goal of the blockchain:
Although it may seem obvious, a critical issue that
must be addressed is the definition of the ultimate
goal of the blockchain to improve healthcare. Beyond
the core benefits of a distributed, immutable,
transparent, and higher trust system, the unique
benefits a blockchain system can provide for
healthcare processes over other existing technologies
must also be assessed. Not all blockchains will have
the same goal(s). For example, some may be designed
to simply lower healthcare transaction-related costs by
improving and automating processes (such as the
use of smart contracts), removing intermediaries,
or reducing administrative burden. Others may
focus on creating mechanisms to drive revenue
generation. Some will prioritize enabling better data
collection, use, and sharing from patients, consumers,
and providers through the offer of incentives (such as
tokens). Further, others may focus on more indirect
benefits such as increasing compliance or preventing
fraud. Eventually, some blockchains may be designed
to achieve multiple goals, yet may start with the most
pragmatic use first.
6. The need for a blockchain: A final question may
simply ask whether the healthcare-related challenge
or goal really needs a blockchain, or if it can be
better facilitated by another form of technology.
Though the above ‘fit-for-purpose’ blockchain frame-
work considerations are not exhaustive, they form a basis
for thinking about how blockchains can be designed in
ways that have shared goals of improving healthcare and
ultimately patient outcomes. Using this framework as a
starting point, this article introduces a set of prominent
use cases in healthcare to further examine what a ‘health’
blockchain may look like in the near future based on on-
going research, published studies, and real-world exam-
ples. The aim of this article is to explore different
perspectives about key design elements, challenges, oppor-
tunities, and best practices for the future health block-
chain landscape. To accomplish this, the article brings
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together a diverse and multidisciplinary group of experts
from academia, the private sector, healthcare startups, and
professional technology associations to discuss use cases
in healthcare records, clinical trial management, medical
credentialing and licensing, genomics and precision medi-
cine, pharmaceutical supply chain, and biomedical re-
search. It closes with a discussion from the IEEE
Standards Association about the importance of setting
technical and industry standards to ensure blockchain in
healthcare moves forward and realizes its potential as a
revolutionary force for 21st century healthcare.
Using privacy-preserving predictive models and
blockchain technology for electronic health
records
Tsung-Ting Kuo (Fig. 4)
Healthcare record management is one of the most im-
portant application domains for blockchain technology
[4, 19, 25, 27]. Blockchain healthcare record manage-
ment focuses on the sharing of data across different
healthcare stakeholders, while preserving the source, prov-
enance and, oftentimes, privacy of such data in a way that
can enable more powerful data analysis and insights from
population health analytics [25, 28–34]. Among healthcare
record applications, this section focuses on an example of
blockchain-based privacy-preserving prediction modeling
that leverages many of the strengths of blockchain
technology [35–37].
In this specific use case, hospitals or healthcare institu-
tions aim at training a machine learning model from the
healthcare records stored in their electronic healthcare
record (EHR) systems, and then using the learnt model to
predict patient outcomes (e.g., the risk of having a certain
condition or disease). Specifically, while targeting rare
conditions/diseases (e.g., Kawasaki disease), there may not
be enough patient records for a single hospital/institution
to learn a generalizable model solely from its own EHR
data. To solve this problem, intuitively, hospitals/institu-
tions can share their data to enlarge the number of re-
cords; however, sharing patient data directly may lead to
privacy risks such as re-identification [38] and data
breaches [39]. Therefore, several privacy-preserving pre-
diction modeling methods have been proposed [40, 41],
enabling the hospitals/institutions to collaboratively train
a predictive model by sharing only partially trained ma-
chine learning models (i.e., a set of aggregated parameters)
instead of patient-level records.
However, these state-of-the-art methods are mainly cen-
tralized (i.e., client-server architecture), which may lead to
several concerns such as the single-point-of-failure on the
server. To mitigate these issues, the combination of block-
chain and privacy-preserving prediction modeling
provides a solution for the hospitals/institutions to collab-
orate and train a generalizable predictive model without
exchanging patient-level data, while obtaining the benefits
of a distributed (i.e., peer-to-peer) architecture without
architectural concerns (e.g., single-point-of-failure). In this
blockchain-based solution approach, the users are the
hospitals or healthcare institutions participating in the
cross-institutional model learning. The data that users’ in-
put is the patient-level data from the EHR, with the same
format and semantic meaning. Importantly, direct data is
not shared across hospitals/institutions, with only the pre-
dictive models learnt from the EHR data being shared via
the blockchain network. In such a blockchain network,
the peers are actually the same as the users.
To ‘validate’ (train a predictive model collaboratively
in this use case) the data (i.e., models), each peer en-
closes their partial models in the transactions (at the
transaction metadata level, as shown in Fig. 2) to create
blocks, retrieves the models from other peers, and then
updates the model using their own EHR data. The
Fig. 4 Dr. Tsung-Ting Kuo is an Assistant Professor of Medicine at
the University of California San Diego (UCSD) Health Department of
Biomedical Informatics (DBMI). He earned his PhD from the National
Taiwan University (NTU) Institute of Networking and Multimedia.
Prior to becoming a faculty member, he was a Postdoctoral Scholar
in UCSD DBMI and received the UCSD Chancellor’s Outstanding
Postdoctoral Scholar Award. He was a major contributor towards the
UCSD DBMI team winning the Office of the National Coordinator
for Health Information Technology healthcare blockchain challenge
in 2016, and also the NTU team winning the Association for
Computing Machinery Knowledge Discovery and Data Mining Cup
competition four times. He was awarded a NIH Pathway to
Independence Award (Parent K99/R00) for a blockchain-based
biomedical and healthcare study. His research focuses on blockchain
technologies, machine learning, and natural language processing
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learning process is conducted in an ‘online’ fashion, such
that the model is updated using only partial data in a se-
quential order. Additionally, training errors are used to
guide the order of the online learning on the blockchain,
based on an intuition that the site containing data with
higher error may provide more information to improve
the model. This iterative learning process is repeated until
a consensus predictive model for all peers is identified. In
this way, blockchain provides specific benefits for problem
solving such as protecting privacy by exchanging models
only, avoiding the single-point-of-failure, and generating
immutable logs for the learning process.
Following this Forum’s framework of the ‘fit-for-pur-
pose’ blockchain design elements, the design type of the
privacy-preserving learning based on blockchain is private.
In terms of data sharing, the models and their
meta-information (e.g., the local training error of a model)
are shared on-chain, while there is no off-chain data shar-
ing. For governance, only participating hospitals and insti-
tutions are included in the blockchain network, and the
incentive of these users/peers to participate is the im-
proved predictive power of the models to glean new in-
sights into patient and population health outcomes.
Ultimately, the goals of this blockchain-based learning
method for health records management include support-
ing comparative effectiveness studies, biomedical re-
search, and eventually patient care.
Blockchain-enabled medical professional
credentialing and licensing
Kevin A. Clauson (Fig. 5)
Processes for the management of healthcare workforce
competencies, including degree verification, credential-
ing, and continuing education, are largely based on leg-
acy systems that can suffer from inefficiencies, lack of
transparency, and avoidable costs [42, 43]. These chal-
lenges are further exacerbated by bad actors, as
highlighted by a survey of hiring managers (n = 2532)
that found 28% of observed job candidates claiming un-
earned academic credentials [44]; this occurs across sec-
tors, including high profile cases like a nationally known
US college football coach resigning days after his hire
after it was unearthed that he had falsified a master’s de-
gree in education [45]. In a more troubling case, a man
falsified both degrees and transcripts to secure a federal
leadership position for a technology role in law enforce-
ment and security [46]. Another recent paper docu-
mented that 89% of human resource and risk experts
reported candidates misrepresent information on appli-
cations [47]. Thus, the dual threats of suboptimal pro-
cesses and bad actors have negatively transformed the
credentialing arena from a seemingly mundane activity
to a time-intensive, cost-inflated pursuit that can even
negatively impact patient safety [48].
Professional credentialing and licensure is also a crit-
ical function of most highly regulated sectors of the
economy, including multiple actors in the healthcare
system. Since the early 1960s, hospitals have been re-
quired to verify the competency of physicians in their in-
stitutions [49]. In general, medical credentialing of
hospital staff and physicians can be time-consuming
and, if processed incorrectly, can lead to increases in
costs (including disrupting a hospital’s revenue cycle),
potential legal liability, and inhibit the ability of a health
system to process reimbursements [50, 51]. Included in
the process is independent verification of certifica-
tions, licenses, qualifications, education, relevant
training (e.g., continuing medical education), board
certifications (if applicable), relevant accreditations,
Fig. 5 Kevin A. Clauson is Associate Professor of Pharmacy Practice
at the Lipscomb University College of Pharmacy & Health Sciences.
His investigation of blockchain for the health supply chain began in
2015 as a follow-up to his previous role as director of a World
Health Organization Collaborating Center. He has received the
Blockchain for Education Collaboration Award, recognizing the
partnership between Lipscomb University and Hashed Health to
build an Ethereum-based platform to allow degree verification. His
research is focused on digital health and his work has generated
coverage by the New York Times, Forbes.com, The Wall Street Journal,
and BBC Radio
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practitioner’s employment history and, in the case of
the US, querying the National Practitioner Data Bank
for negative information. Further, providers may
maintain independent credentials with multiple sys-
tems based on their admitting privileges and may also
have practiced in another state [52].
In its simplest terms, a blockchain medical credential-
ing solution would act as a decentralized data directory
where data on the provider’s identity could be verified to
its trusted source and continuously updated and recon-
ciled to ensure trust and confidence in the provider’s
ability to practice. One model envisions accreditors, hos-
pitals, medical schools and other educational institu-
tions, licensing boards, national health agencies, and
other sources of credentialing information serving as
nodes and participants in the blockchain (potentially re-
ducing the need for medical credentialing services and
other intermediaries). Other models would position a
blockchain structure that served as either interstitial or
as second layer solutions that could provide connectivity
for all of the current data silos involved in credentialing.
Analogous to the ‘fit-for-purpose’ model that leverages
blockchain enhancement for health supply chain man-
agement (as discussed later by TKM and MP), medical
credentialing has similarly distributed sets of stake-
holders that require varying levels of permissions across
the assets’ lifecycle (e.g., in this case, the information re-
lating to a provider’s identity).
One such credentialing lifecycle tool that has been con-
ceived is the Comprehensive Learner Record, which in-
cludes coursework, degree(s), competencies, co-curricular
activities, experiential learning, microcredentials, and pro-
fessional (e.g., medical) credentials that could map into li-
censure and continuing medical education [53]. The
Comprehensive Learner Record also includes the Open
Badges functionality, which in turn is data aligned with
Blockcerts standards. Blockcerts has separately been ad-
vanced as an “open standard for blockchain credentials”
[54]; notably, initial Blockcerts support was for public
(e.g., Bitcoin and Ethereum) blockchains, with expansion
to other blockchains outlined in their roadmap.
Reflecting again on the ‘fit-for-purpose’ model, this use
case can be characterized as individual centric rather
than process centric. As such, identity is central to all of
these processes, but can be approached via public, pri-
vate, hybrid, or consortium designs. One such example
of a public design is through the Decentralized Identity
Foundation, which aims to use an Identity Hub architec-
ture [55] to help accomplish this goal.
Within this broader framework, efforts to leverage
the strengths of blockchain to secure provider identities
and credentialing include private (e.g., Piper Jaffray),
government (e.g., State of Illinois), commercial (e.g., Pro-
fessional Credentials Exchange), and educational (e.g.,
Lipscomb University) entities [2]. One collaborative pilot
between state government and industry in this area pro-
poses a blockchain-based registry for data sharing, but
also adds smart contract functionality to ‘automate
workflow’ for medical licensure tied to more than one
state in order to further enhance efficiency and reduce
costs [56].
While educational credentialing remains limited in
scope and onerous to conduct for many institutions of
higher education, and medical credentialing and licen-
sure can be disproportionately resource intensive,
thoughtfully designed blockchain-based systems and the
enhanced functionality of smart contracts offer promise
as a means to contemporize these fundamental but anti-
quated elements of education and healthcare.
Can we use blockchain to improve clinical trial
management?
Basker Gummadi (Fig. 6)
“If you have a hammer, everything looks like a nail” –
technology professionals tend to assume their favorite
technologies are the solutions for virtually any problem.
The ‘hammer’ bias in technology has always been there,
and the hammer keeps changing based on the latest
trend, with currently trending technologies being block-
chain, artificial intelligence, and robotic process automa-
tion [57]. However, a better approach is to identify the
business problems that need solving and subsequently to
evaluate the available technologies, tools, and solutions,
while also assessing the attributes and features that are a
‘perfect fit’ to solve that problem. No single tool or
process is a ‘silver bullet’ or ‘golden hammer’; it is the
combination of the different technologies and tools, se-
lected based on the problem being tackled, and their in-
dividual attributes, that are best suited for problem
solving. This approach ties in well to the ‘fit-for-purpose’
framework that views blockchain technology as modular
and with different technology features that can be cus-
tomized; it also applies to blockchain development in
healthcare verticals like clinical trial management.
The benefits for blockchain in clinical trials manage-
ment includes moving stakeholders into a distributed
network with processes that can be more efficient when
you eliminate the need for intermediaries [16]. This do-
main of healthcare is ripe to leverage core benefits of
blockchain technology such as transparency, disinter-
mediation, immutability, auditability, and trust. From a
business perspective, a typical clinical trial process is ex-
pensive and involves numerous stakeholders [58]. Thus,
blockchain technology can help clinical trial sponsors,
patients/subjects, principal investigators and site admin-
istrators that conduct the clinical trial, Institutional
Review Boards, and regulatory authorities.
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Once we have identified the different actors involved in
clinical trial management, we can then identify challenges
and map blockchain solutions based on a ‘fit-for-purpose’
approach. Some of the most pressing challenges in clinical
trials include (1) access and management of clinical trial
data; (2) data integrity and provenance for clinical trial
processes for regulatory purposes; (3) updating and main-
taining patient consent; and (4) patient recruitment.
Below, some blockchain approaches to address clinical
trial management challenges are described, which also il-
lustrate the variety of blockchain designs.
Arguably, the most important stakeholder in a clinical
trial is the patient; currently, when a patient leaves a
clinical trial, they rarely have access to any of their clin-
ical trial results. If a sponsor wants to share their clinical
trial data with a patient, they can easily do so without a
blockchain, but it is more beneficial for the patient to be
part of a network where multiple sponsor companies
share data on the network and data is verifiable to the
patient’s identity [59]. On a blockchain platform,
additional sources of data, such as from hospitals, care
providers, genomic data, proteomic data, and other
medical data (e.g., from medical devices), can be added
by enabling the respective data providers or systems to
share the data with the patient in a blockchain-enabled
digital wallet or other patient-centric database.
More robust data access can also enable better patient
recruitment into clinical trials. With recruitment costs
ranging between US$ 2 billion and US$ 3 billion (also
depending on the phase of the clinical trial), this repre-
sents a major barrier that continues to increase [60].
Blockchains can aggregate patient and trial data that is
anonymized or else subject to patient-driven permissions
[59]. In this way, patients and sponsors/sites could con-
nect better with eligible patient populations where there
is mutual interest for trial participation. With this chal-
lenge, permissioned-based blockchains with the patient
at the center of data governance might be the best
approach.
Data integrity and data provenance are key in clinical
trials. Sponsors and investigational sites have to prove
data provenance and respond to queries from regulatory
authorities to help ensure that clinical results maintain
their integrity from data capture through to interim and
final analyses. This process is burdensome and time con-
suming and increases the costs of a clinical trial’s data
sharing and management procedures [61]. Blockchain
has an architecture that can transparently show the
provenance of the data from the origin to the final clin-
ical summary report. The underlying trust in the data is
enhanced, accelerating the regulatory approval process,
and regulatory authorities will be better equipped to
evaluate clinical trial results and determine if a treat-
ment is safe and beneficial to patients. With regards to
clinical trial data management, the design of a block-
chain will likely be on a private network, with only
trusted nodes associated with the study protocol. In the
event of a regulatory inquiry, private key management
could also enable a regulator to inspect the data for
integrity [61].
Another challenge arises when sponsors are planning a
clinical study, as the protocol often goes through several
revisions and is revised even after patient enrollment to
provide the best outcome for the patients. Sites man-
aging the trial have to ensure appropriate patient con-
sent (often via paper format) with the latest version of
the protocol, which is a challenge as consent collection
is a dynamic process. Sponsors are accountable for this
process, and it is a key area of focus for regulatory au-
thorities in their inspections. In response, sponsors can
build a consent workflow using blockchain to implement
a process allowing for collection of patient informed
consent (including, potentially, e-consent through smart
contracts), which is bound to protocol revisions. This
Fig. 6 Basker Gummadi is the IEEE Lead for Digitalization of Clinical
Trials. He works at Bayer Corporation as Digital Innovation Senior
Manager/Deputy Director, and leads a community focused on
bringing together stakeholders in the pharma industry and
academia to identify business cases for clinical trials using blockchain,
artificial intelligence, robotic process automation, and big data. He is
the current team lead for projects focused on designing clinical trials
to be more patient centric using blockchain technology. Prior to
joining Bayer, Basker held various positions in the pharmaceutical
industry, including Business Solution Manager at Hoffman-La-Roche,
Assistant Director at Schering Plough, and Senior Analyst at Bristol
Myers Squibb
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process would allow for a built-in layer of transparency
and traceability by time-stamping each step of a patient’s
consent and potentially automating it via set rules in
smart contracts.
The fundamental design elements of clinical trial
blockchains requires a private blockchain. In this model,
the different stakeholders of sponsors, sites, regulatory
authorities, and data providers (claims, proteomic, gen-
omic, hospitals, and physician’s offices) can all be nodes,
and patients can act as the participants. In terms of data
sharing, the clinical trial data will likely reside within the
respective company’s database; the patient will be able to
access their data via a pointer to their data on-chain
through a unique hash, enabling the patient to have con-
trol of their data and share their clinical trial results.
For shared governance of a clinical trial blockchain,
only screened and selected patients who are permis-
sioned, with similarly permissioned institutions, would
be included in the blockchain network. The incentive for
these users/peers is the improved predictive power of
the models associated with clinical trial data, collabora-
tively trained in a distributed and privacy-preserving way
(as discussed by T-TK above).
Ultimately, clinical trial blockchains show immense
promise to be one of the first successful use cases enter-
ing production and show real-world benefits in the
healthcare vertical. Shared value, lowering costs, enhan-
cing regulatory compliance, and streamlining clinical
trial processes all position blockchain as a critical tool in
the future of clinical trial management.
Blockchain technology to advance biomedical
research?
Robert Barkovich (Fig. 7)
Blockchain is being heralded as a breakthrough tech-
nology for healthcare and the life sciences. As an ex-
ample, the Icahn School of Medicine at Mount Sinai in
New York opened a Center for Biomedical Blockchain
Research in July of 2018 [62]. Nevertheless, there re-
mains much skepticism about blockchain in these indus-
tries, in particular regarding how it can solve real-world
problems and whether there will be more broad-scale
adoption. Blockchain technology shows great promise
for biomedical research as it has the potential to address
many long-standing challenges in the field. These issues
include authenticity and integrity of data, data proven-
ance, consent, data privacy, and data sharing. It also has
the potential to enhance efforts towards promoting
‘open science’ to enable transparency, accessibility,
reproducability, and mobilization of scientific knowledge
and data through collaborative networks [63]. In this
section, the uses and features of blockchain technology
for biomedical research will be discussed.
The nature of biomedical research data implies that much
of the data will be considered protected health information
and/or personally identifiable information. All blockchain
systems offer immutable data and an easily accessible audit
trail. Most public blockchain implementations offer ano-
nymity, but not data privacy, as all transactions are transpar-
ent and visible to the general public. With private or
permissioned blockchains, a user must be given credentials
to access the blockchain. Additionally, there are hybrid
blockchains that can act as both a public and private chain
at different times. In the vast majority of biomedical data
use cases using protected health information or personally
identifiable information, a private or hybrid system is
necessary.
Data is retrieved from many sources in biomedical re-
search, both from within a lab and between labs. In
order to ensure reproducibility of the research, it is very
important to have access to the data, be able to prove
that the data is authentic, show a full history of what has
happened to each data point (data provenance), and be
able to show that the data is the same at the time of ana-
lysis as it was when it was collected (data integrity and
reproducibility). Blockchain technology is ideal for this
purpose as it can mathematically prove the integrity of
the data and record the full history of a data point
through hash chains. Provenance, in particular, is ex-
tremely important for research as it is directly related to
data quality [64]. A blockchain-based system can record
not only references to the original data but also every
transformation and function applied to the data, leading
Fig. 7 Robert Barkovich is a product leader and entrepreneur with
more than 15 years of experience on the software and IT side of
healthcare and life sciences. Robert runs Productive Consulting and
is the founder of Health Linkages Inc., a company focused on
solving the data provenance problem in the healthcare and life
sciences industries
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to better reproducibility and potential detection of falsi-
fied data.
With the onset of the GDPR [65] in the European
Union and changes to the Common Rule in the United
States [66], consent has moved to the forefront as a con-
cern for clinical trials data and other research data. Con-
sent can be recorded in a mathematically provable and
immutable fashion by blockchains. Smart contracts,
which are self-executing contracts between two parties,
have been utilized to enable quick and efficient record-
ing of consent (as mentioned above by BG) [16, 67]. The
use of smart contracts has also been outlined by the
Pharmaceutical Users Software Exchange for health data
mining in a way that patients/subjects can monetarily
benefit from the use of their personal data for research
purposes [68].
An increasing volume of biomedical research data is
being directly obtained from devices. Distributed ledger
technology has been shown to ensure the authenticity
and integrity of data from wearables and IoMT devices
[10] as well as in the more general Internet of Things
(IoT) community [69]. With this increasing amount of
data, it has also been shown that this technology can be
used as a foundational layer for artificial intelligence and
machine learning approaches to classify and analyze ‘big
data’ [5].
Blockchain technology features exhibit significant
promise for biomedical research applications, but many
challenges remain. The technology is still evolving and
enabling a wider range of use cases by the day. Amidst
all this interest, it is important to remember that block-
chain technology is not a panacea for all issues related
to biomedical research data or open science. However,
when combined with other technologies, it has the
potential to provide a solution that can address the
long-standing challenges related to reproducibility, in-
tegrity, and trust in biomedical research.
Blockchain technology set to modernize the
pharmaceutical supply chain?
Tim K. Mackey (Fig. 1) and Maria Palombini (Fig. 8)
In the era of globalization, most supply chains now
span multiple countries, actors, and products. Pharma-
ceutical supply chains are no exception and are charac-
terized by complexity and fragmentation [70], including
the different actors who participate in the drug supply
chain such as manufacturers, wholesalers, repackagers,
logistic providers, regulators, hospitals, pharmacies/dis-
pensers and, of course, the end user patient [71]. They
are global in nature, often involving trading partners in
several different countries, oftentimes subject to a multi-
tude of different trade, legal, and regulatory regimes.
Throughout the health supply chain, the potential for
drugs to experience breakdowns in management, quality,
safety, or authenticity are a serious concern for public
health [70, 72].
Blockchain has the potential to address many pharma-
ceutical supply chain challenges, though a prominent
use case has been its application to combating falsified
and substandard (i.e., counterfeit) medicines [12, 21, 70,
73]. Tackling this issue focuses on developing blockchain
solutions that can enable trust and verification of supply
chain data as medicines traverse the global supply chain,
while also enabling participants to identify potential in-
filtrations of fake medicines through greater visibility of
rogue supply chain transaction data [12, 21]. These
Fig. 8 In 2017, Maria Palombini joined the IEEE Standards
Association with a directive to build communities and advance
initiatives to develop standards for enterprise adoption of emerging
technologies. Her area of focus includes research on challenges and
opportunities in integrating cutting-edge technologies such as
artificial intelligence, Internet of Things, machine learning, virtual/
augmented reality, smart materials and blockchain/distributed ledger
technology (DLT) into the areas of pharmaceuticals, precision
medicine, agriculture, and digital citizenship. She founded the
Pharma Blockchain Initiative, which seeks to educate all stakeholders
– patients, regulatory personnel, clinicians, pharmaceutical
professionals, scientists, technologists – on the benefits and
challenges of applying blockchain/DLT platforms to enable a
patient-centric identity system that would benefit both the patient
and critical operational areas of the pharmaceutical value chain. The
work includes educating and building a global collaborative
community that can reach consensus on technical standards and
new protocol guidance required to enable industry buy-in for these
emerging technologies and their breakthrough applications. Maria
currently holds an MBA from the Rutgers Graduate School of
Business and a BA and BS from Rutgers College at Rutgers
University, the State University of New Jersey. She is an
accomplished leader, public speaker, and writer, having presented
at various industry events and published blogs and articles in
trade publications
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systems could also act as a data architecture to enhance
interoperability, track-and-trace, and e-pedigree require-
ments, all important characteristics of a modern digital
supply chain [70].
Though different approaches have been explored, in-
cluding by the Center for Supply Chain Studies, virtually
all of these conceptual models focus on private or con-
sortium business blockchains that adopt GS1 (open glo-
bal standard for tracking healthcare products commonly
used in barcodes) pedigree standards, with different de-
grees of permissions to transaction data on and off chain
[74]. However, a major challenge to these drug safety-
and regulatory-centric blockchains is governance,
namely who will participate in the blockchain, how
will data be validated, and most importantly, how will
sensitive and confidential supply chain data be shared
or not among participants? Many of these challenges
necessitate building a consortium of interested parties
that can agree upon these rules before a solution is
even developed.
Several large companies and blockchain startups are
active in the development of pharmaceutical supply
chain blockchains [71]. Research and experimentation is
also occurring, with one example of a published protocol
that proposes a pharmacosurveillance blockchain system
on a simulated network using distributed applications,
smart contracts, and prototype instances built on both
the Ethereum and Hyperledger fabric blockchain plat-
forms [12]. However, design elements to ensure these
blockchains are ‘fit-for-purpose’, scalable, and can with-
stand real-world testing remain in the early stages.
Uniquely, global pharmaceutical supply chains are also
undergoing a period of policy modernization. Specifically,
the FDA’s Drug Supply Chain Security Act outlines the ne-
cessary steps to implement an electronic, interoperable
system to identify and trace prescription drugs distributed
in the US [75]. This will enhance the FDA’s ability to pro-
tect consumers, including from drugs that may be coun-
terfeit, stolen, contaminated, or otherwise harmful. The
Drug Supply Chain Security Act also has a counterpart in
the European Union, where the EU Falsified Medicines
Directive requires measures to prevent falsified medicinal
products from entering the legal supply chain by demand-
ing safety features (including a unique product identifier
and anti-tampering devices on packaging) to ensure iden-
tification and authentication [76].
Importantly, both of these policy instruments have
regulatory requirements that can be facilitated via block-
chain technology. For example, both policies require a
unique identifier (through the use of serialization) to
verify drug authenticity to deter counterfeit, or any other
suspect medicine, from reaching patients. However,
there are differences, with the EU Falsified Medicines
Directive using a centralized approach where drug
manufacturers upload serial numbers to a centralized
EU regulator database, allowing distributors to connect
and verify the authenticity of the drug. In the US, there
is no centralized regulator database planned and it will
be logistically challenging to have distributors integrate
their data with that of pharmaceutical manufacturers.
Thus, blockchain offers a potential solution to meet the
needs of both markets to better ensure the integrity of
serialization data and the provenance of pedigree and
track-and-trace information. Blockchain systems could en-
able pharmaceutical manufacturers to share their serial
numbers on the blockchain – decentralized and distrib-
uted with timestamps – where wholesalers, dispensaries,
and prescribers would access to verify the provenance of
the drug.
However, blockchain technology is not the panacea for
combating the global criminal trade in falsified and sub-
standard medicines. Though a noble goal, the unique
challenges associated with the criminal nature of this
trade, the presence of the grey market (i.e., access to medi-
cines outside of the controlled supply chain such as the
Internet), and the need for other forms of technology to
appropriately authenticate and verify the physical product
(e.g., analytical chemistry and anti-counterfeiting technol-
ogy), may render blockchains ineffective when tested in
the real-world and against nefarious actors [70, 77]. Thus,
other use cases in the medicines supply chain vertical, in-
cluding enhancing pharmaceutical public procurement,
pharmacovigilance, recall management, returnable sales,
enabling cold chain management integration with IoT,
and even streamlining licensure and credentialing of sup-
ply chain actors, may have greater short- and even
long-term utility than the fake medicines use case.
Adoption of blockchain into health supply chains is
moving slower than in other industries (e.g., food supply
and diamond supply chains). Illustrating some chal-
lenges, a study conducted by the IEEE Standards Associ-
ation in 2017 on the state of blockchain adoption for the
pharmaceutical supply chain found that three of the
most frequently cited barriers of adoption among 300
qualified respondents (34% manufacturers, 33% distribu-
tors, and 33% retailers) were user buy-in/acceptance, in-
tegration into existing networks, and challenges (i.e.,
training) of implementing new technologies [78]. The
cost of adoption and implementation is a primary chal-
lenge for supply chain stakeholders, as these blockchain
solutions may not inherently drive revenue, but would
instead enhance compliance and, hopefully, in the
process lower costs or mitigate risk. These benefits may
be hard to quantify, particularly in the context of fake
medicines where the scope and prevalence of this activ-
ity is not well known [79]. This may position other
cheaper technologies as more attractive alternatives to
blockchain solutions.
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Finally, the true value of a pharmaceutical blockchain
may not be found in specific use cases. Instead, unlock-
ing the potential of blockchain might best be used for
broader goals of accelerating health supply chain
modernization, unlocking data to improve supply chain
performance and management, increasing transparency
to enhance governance and accountability, moving to-
wards regulatory harmonization of supply chain net-
works, and addressing issues regarding ‘last mile’
barriers in medicines access, quality, and affordability.
Entering the genomics age with the help of
blockchain technology
George Church (Fig. 9), Dennis Grishin (Fig. 10), and
Kamal Obbad (Fig. 11)
The development of next-generation DNA sequencing
technologies has resulted in exponentially declining
costs of human genome sequencing and has made per-
sonal genome sequencing affordable to many people.
This unprecedented advancement has seemingly brought
us closer to an age of genomic data-driven medicine and
drug development. However, though there has been an
increase in direct-to-consumer genetic testing, this
transformation continues to be delayed due to lagging
consumer adoption of whole genome sequencing and si-
loed datasets [80].
We have explored various approaches to popularizing
personal genome sequencing and making genomic data
more accessible. In 2005, we initiated the Personal Gen-
ome Project – a public genomic database – and have
thus far recruited thousands of volunteers who have
agreed to be sequenced and share their genomic data
[81, 82]. In 2015, we helped make personal genome se-
quencing available for less than $1000, a price point that
marked an important barrier broken towards an era of
precision medicine. Our experiences have taught us two
important lessons. Firstly, that few people are comfort-
able publicizing their personal genetic information and
many are concerned about privacy policies of personal
genomics companies [83]. Therefore, while the Personal
Genome Project has made admirable progress, it has not
experienced exponential growth. Secondly, most people
do not value personal genome sequencing since the
probability that they will immediately and significantly
Fig. 9 George Church is a Professor at Harvard and MIT. His lab
developed methods used for the first genome sequence (1994) and
million-fold cost reductions since (via NGS and nanopores), plus
barcoding, DNA assembly from chips, and genome editing, writing
and recoding
Fig. 10 Dennis Grishin is CSO and co-founder of Nebula Genomics.
He studied biology at the University of Freiburg and computer science
at Harvard University and is a recipient of the German National
Academic Foundation Fellowship. He is currently a Boehringer
Ingelheim PhD Fellow in Genetics and Genomics at Harvard University
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benefit from it is relatively low [84]. Thus, decreasing se-
quencing prices has not been enough to incentivize a
mass adoption.
These lessons have led us to the conclusion that
strong data privacy guarantees and novel incentive
mechanisms are needed to drive genomic data gener-
ation and encourage data sharing. Blockchain technology
can help catalyze a genomics data revolution by reducing
personal genome sequencing costs, democratizing gen-
omic data ownership, and enabling transparent genomic
data sharing. This is made possible by two core proper-
ties of blockchain networks.
First, blockchain facilitates the creation of decentra-
lized networks that enable participants to exchange data.
The blockchain typically serves as an access control layer
and can be used to implement a cryptocurrency that cre-
ates economic incentives to share data that is stored off
chain. These general design principles can be applied to
create a platform that enables individuals to control ac-
cess to their personal genomic data and incentivizes data
sharing with researchers and others who might benefit
from access to the data. However, blockchain technology
must be adapted to accommodate the unique challenges
of genomic data. In particular, genomic data differs from
many other data types in its scarcity, which is caused by
the low adoption of personal genome sequencing. Thus,
in addition to data access sharing, a genomic data ex-
change platform must also drive genomic data
generation. Therefore, network protocols must be
adapted to incorporate genomic data generators (DNA
sequencing providers) as a third type of network partici-
pant. Together, genomic data generators, sellers, and
buyers can create an economy that shifts sequencing
costs from data sellers to data buyers and thereby drives
genomic data generation.
Second, blockchain can act as a public ledger that im-
mutably stores transaction records. This property can be
leveraged to implement transparent consent manage-
ment that incentivizes data sharing. To this end, data
owners can add time-stamped entries to the blockchain
that allows data buyers with permission to access their
data. However, this functionality must also be ‘fit-for--
purpose’ to ensure protection of highly sensitive per-
sonal genomic data. In particular, an effective consent
management system for genomic data must require data
buyers to reveal their identity (e.g., name and institu-
tional affiliation) while data owners must be able to re-
main anonymous to protect their privacy. This can be
implemented with a permissioned blockchain that allows
only verified data buyers to access the network. Thus,
transaction validator nodes must be operated by a con-
sortium of collectively trusted ‘data guardians’. Such
nodes can, for example, be operated by independent
third-party, non-profit organizations whose aim is to
support biomedical research and that can act as a fidu-
ciary for a data owner’s interest.
Blockchain has been described as a revolutionary tech-
nology that will transform many different industries. Yet,
for the nascent field of genomics, precision medicine,
and pharmacogenomics, blockchain can be a truly enab-
ling technology with an unparalleled impact.
The future of the health blockchain: promising
use cases and the importance of technical
standards setting
Maria Palombini (Fig. 8)
There is no doubt that for every touchpoint in the
healthcare ecosystem there could be a blockchain appli-
cation. The reason is simple – the healthcare ecosystem
is nourished with data generation and sharing, from bio-
medical research in a lab with cell/tissue analysis all the
way through to insurance payments when care is pro-
vided. However, in order to have a functional healthcare
ecosystem, the data needs to be shared to all the critical
parts so that patient care has continuity [85]. The neces-
sity to share data throughout the ecosystem is what
makes blockchain a viable application for healthcare.
The many features of blockchain technology lend
themselves to one undisputable reality, namely the abil-
ity to evenly negotiate the tension between data sharing
and privacy. For decades, healthcare delivery
Fig. 11 Kamal Obbad is CEO and co-founder of Nebula Genomics.
He attended Harvard University, where he conducted research on
neurological and embryological development. After Harvard, Kamal
joined Google and worked within the research and machine
intelligence organization. He is a recipient of the Gates-Cambridge
Fellowship for the pursuance of graduate studies in advanced
computer science
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organizations, pharmaceutical companies, physicians,
and health service providers have relied on policy to
maintain a valuable asset, such as patient data, siloed
and protected. In the absence of technology platforms
that could guarantee an equal balance of patient data
sharing and privacy, these organizations not only bene-
fitted from leveraging the data but also compromised it.
The reality of the need to collaboratively share and
maintain the privacy of healthcare data has resulted in 2
years of blockchain experimentation, with mixed results.
This period of early health blockchain exploration has
been characterized by the rise and fall of proof-of-con-
cepts and pilot projects that have yet to enter into ro-
bust production and usability. However, there is now
growing ‘consensus’ and progress on use cases (e.g., drug
supply chain, clinical trials and research, and patient
centric identity) deemed viable for blockchain and
health, some of which have been covered in this Forum
article.
In addition to these use cases, one of the greatest op-
portunities that blockchain offers is to accelerate preci-
sion medicine (as previously discussed by GC, DG, and
KO). Specifically, patient-centric identity empowers the
patient with rights to consent to, and choose how to, use
their data in exchange for health services or even com-
pensation. It also provides auditability of whom, when,
and where personal health data are utilized. For ex-
ample, based on our discussions with patient advocacy
groups, patients who suffer from rare, chronic or ter-
minal diseases, are more incentivized to find or contrib-
ute to a therapy or treatment. However, these same
patients often do not have access to, or portability of,
their healthcare profiles, which can inform clinical trial
matching, access to potential experimental treatment, or
aid in drug discovery.
Blockchain technology can address the issue of health-
care data silos that are provider-centric and not
patient-centric by enabling open health data exchange
markets driven by patients. These open health data mar-
kets will not be the average data warehouse; they will be
populated with what is termed ‘V3 Data’ – validated,
verified, and valuable. Market data will not be passively
collected from mobile or internet searches or generic
wearable data; rather, it would consist of clinically
verified diagnostics, treatment outcomes, real-world evi-
dence, genetics, DNA profiling, and more. Some exam-
ples of current and operational personal health data
exchanges include Embleema, which launched the first
patient-driven, HIPAA-compliant, health records block-
chain aiming to solve the challenges associated with the
collection and safe sharing of real-world evidence [86],
and Shivom, which is creating a global platform for the
secure storage and sharing of genomic data [87]. Thus,
the open health data market creates many opportunities
that were once considered impossible, including (1) pla-
cing the patient as the driver of data through empower-
ment and the right to consent to sharing their data,
receiving compensation, and viewing audits of transac-
tions; (2) creating a more competitive marketplace for
smaller pharmaceutical and biotech companies that cur-
rently cannot afford to compete in clinical research and
development because the cost of generating data out of
trials is prohibitively expensive; and (3) providing access
to much needed data to address challenges in population
health and precision medicine.
However, in order to drive compliant and efficient
blockchain adoption at larger scale in life science and
health applications, technical data standards and regula-
tory policies need to be developed to ensure proper proto-
cols and policies are created as it relates to distribution,
management, and control of patient data [15]. Regulatory
agencies do not create technical standards and standards
organizations do not create policy; however, regulatory
agencies are more likely to adopt policy and guidance on
technologies that have market-driven, consensus-built
technical standards. Therein lies the critical link between
policy and standards setting.
Some have argued that technical standards can con-
strain innovation in uncertain markets [88]. The reality
is that, if new technologies enter the market without
some credibility, they will not be adopted for industrial
nor consumer applications. Thus, market-driven and
consensus-built technical standards directly address
some of the uncertainties associated with the adoption
of new technologies such as blockchain, including
supporting interoperability with existing technology sys-
tems, reducing the cost of integration by removing the
need for customization, establishing credibility (through
consensus-built standards), enabling industry-wide
adoption, driving competition through the creation of
open-platform standards (‘platform agnostic’), and offer-
ing the ability to harmonize policy specifically around
the use of technologies (where possible).
There are blockchain standards that have been pub-
lished and/or are currently in development from both an
industrial application and technical perspective [78]. Some
of the currently published standards include the Chain
Open Standard for Finance [89] and the Enterprise Ether-
eum Alliance [90]. Technical standards not only alleviate
the barriers of wide-scale adoption of technologies such as
blockchain in industrial applications but also enable the
convergence of other cutting-edge technologies such as
IoT, 5G, and artificial intelligence to interoperate with the
blockchain. Specifically, blockchain standards for pharma-
ceuticals or any other health application cannot be written
in absence of existing industry standards for other inter-
facing technologies or processes. For example, to develop
a pharmaceutical supply chain track-and-trace blockchain
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standard, it would need to include GS1 Standards that
provide a common language to identify, capture, and share
supply chain data [91]. Additionally, blockchain for clin-
ical trial data sharing will need to utilize the HL7 (Health
Level Seven International) standards, which provide a
framework (and related standards) for the exchange,
integration, sharing, and retrieval of electronic health in-
formation [92]. Along with the release of HL7 Ver-
sion 2, the FHIRChain (Fast Health Interoperability
Records + Blockchain) was launched [93], which is a
blockchain-based architecture for shared clinical data
that can enable blockchain solutions focused on
healthcare record management.
As expected, technologists and industry executives are
focused on the now – successfully implementing a fully
operational blockchain for an identified use case. How-
ever, standards organizations need to focus on develop-
ing solutions for the challenges that will arrive
tomorrow. The roll out of multiple blockchains will re-
quire more standards as it relates to chain-to-chain
interoperability, providing insight to regulatory agencies
for establishing policies and guidance, and continuous
education for industry stakeholders, as well as patients.
The greatest benefits of blockchain are yet to be real-
ized. However, the outcomes of successful and failed
blockchain pilots will eventually lead to the promise of
patient-driven healthcare systems in the form of open
health data markets and precision medicine, finally
reaching the patient.
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